https://eventris.app/ https://eventris.app/features/ https://eventris.app/solutions/ https://eventris.app/solutions/medical/ https://eventris.app/solutions/security/ https://eventris.app/solutions/venues/ https://eventris.app/solutions/organisers/ https://eventris.app/solutions/facilities/ https://eventris.app/solutions/food-and-beverage/ https://eventris.app/solutions/traffic/ https://eventris.app/solutions/agencies/ https://eventris.app/videos/ https://eventris.app/pricing/ https://eventris.app/about/ https://eventris.app/contact/ https://eventris.app/download/ https://eventris.app/privacy-policy/ https://eventris.app/terms-and-conditions/ https://eventris.app/cookie-policy/ https://eventris.app/modern-slavery/ https://eventris.app/account-deletion/ https://eventris.app/medicines/ https://eventris.app/drug-safety/2026-10-15 https://eventris.app/drug-safety/amiodarone-essential-monitoring-and-supervision-reminder/2026-05-20 https://eventris.app/drug-safety/finasteride-and-dutasteride-updated-psychiatric-and-sexual-dysfunction-warnings/2026-05-11 https://eventris.app/drug-safety/nasal-decongestant-sprays-rebound-congestion-and-overuse-risk/2026-05-03 https://eventris.app/drug-safety/falsified-mounjaro-kwikpen-15mg-detected-in-uk/2026-05-02 https://eventris.app/drug-safety/ixchiq-chikungunya-vaccine-temporarily-restricted-in-adults-aged-65/2026-05-03 https://eventris.app/drug-safety/ixchiq-chikungunya-vaccine-age-restrictions-updated-following-safety-review/2026-05-03 https://eventris.app/drug-safety/semaglutide-and-risk-of-vision-loss-naion/2026-05-03 https://eventris.app/drug-safety/glp-1-agonists-strengthened-warnings-on-acute-pancreatitis-risk/2026-05-03 https://eventris.app/drug-safety/isotretinoin-prescribing-guidance-and-risk-minimisation-updates/2026-05-03 https://eventris.app/drug-safety/updated-safety-information-for-gabapentinoids-benzodiazepines-and-z-drugs/2026-05-03 https://eventris.app/drug-safety/rybelsus-semaglutide-formulation-transition-and-medication-error-risk/2026-05-03 https://eventris.app/drug-safety/mesalazine-and-idiopathic-intracranial-hypertension-risk/2026-05-03 https://eventris.app/drug-safety/isotretinoin-prescribing-guidance-updates/2026-05-03 https://eventris.app/drug-safety/medsafetyweek-2025-collective-action-to-improve-medicines-safety/2026-05-03 https://eventris.app/drug-safety/paracetamol-in-pregnancy-remains-safe-no-autism-link/2026-05-03 https://eventris.app/drug-safety/rsv-vaccines-and-guillain-barre-syndrome-risk-in-older-adults/2026-05-03 https://eventris.app/drug-safety/valproate-reproductive-risk-updated-safety-materials-now-available/2026-05-03 https://eventris.app/drug-safety/thiopurines-and-intrahepatic-cholestasis-of-pregnancy/2026-05-03 https://eventris.app/drug-safety/kaftrio-psychological-side-effects-in-cystic-fibrosis-treatment/2026-05-03 https://eventris.app/drug-safety/saba-overuse-in-asthma-safety-reminder-and-prescribing-guideline-changes/2026-05-03 https://eventris.app/drug-safety/fezolinetant-veoza-liver-injury-risk-monitoring-guidance/2026-05-03 https://eventris.app/drug-safety/prolonged-release-opioids-post-operative-pain-indication-removed/2026-05-03 https://eventris.app/drug-safety/january-2025-medicine-recalls-and-safety-notifications/2026-05-05 https://eventris.app/drug-safety/valproate-two-specialist-review-now-required-for-new-patients-under-55/2026-10-15 https://eventris.app/drug-safety/glp-1-agonists-and-pulmonary-aspiration-risk-during-anaesthesia/2026-05-02 https://eventris.app/drug-safety/december-2024-medicine-recalls-and-safety-letters/2026-05-05 https://eventris.app/drug-safety/november-2024-medicine-recalls-and-safety-letters/2026-05-05 https://eventris.app/drug-safety/medsafetyweek-2024-yellow-card-reporting-campaign/2026-05-02 https://eventris.app/drug-safety/october-2024-medicine-recalls-and-safety-updates/2026-05-05 https://eventris.app/drug-safety/glp-1-receptor-agonists-side-effects-and-misuse-risk/2026-05-02 https://eventris.app/drug-safety/insulin-pumps-and-cgm-equipment-report-safety-concerns-via-yellow-card/2026-05-02 https://eventris.app/drug-safety/bromocriptine-blood-pressure-monitoring-essential/2026-05-02 https://eventris.app/drug-safety/september-2024-letters-and-medicine-recalls-summary/2026-05-02 https://eventris.app/drug-safety/august-2024-medicine-recalls-and-safety-updates/2026-05-05 https://eventris.app/drug-safety/valproate-use-in-men-and-contraception-advice/2026-05-02 https://eventris.app/drug-safety/yellow-card-biobank-study-on-genetic-links-to-doac-and-allopurinol-side-effects/2026-05-02 https://eventris.app/drug-safety/july-2024-medicine-recalls-and-safety-letters/2026-05-05 https://eventris.app/drug-safety/epimax-ointment-risk-of-eye-injury-if-used-on-face/2026-05-02 https://eventris.app/drug-safety/june-2024-medicine-recalls-and-safety-letters/2026-05-05 https://eventris.app/drug-safety/topiramate-new-pregnancy-prevention-programme-requirements/2026-05-02 https://eventris.app/drug-safety/warfarin-and-tramadol-critical-drug-interaction-risk/2026-05-02 https://eventris.app/drug-safety/may-2024-medicine-recalls-and-safety-updates/2026-05-05 https://eventris.app/drug-safety/topical-steroids-new-labelling-and-withdrawal-risk-reminder/2026-05-05 https://eventris.app/drug-safety/april-2024-medicine-recalls-and-safety-updates/2026-05-04 https://eventris.app/drug-safety/finasteride-psychiatric-and-persistent-sexual-side-effects/2026-05-02 https://eventris.app/drug-safety/montelukast-and-neuropsychiatric-reactions-in-all-ages/2026-05-04 https://eventris.app/drug-safety/march-2024-medicine-recalls-and-safety-updates/2026-05-04 https://eventris.app/drug-safety/february-2024-medicine-recalls-safety-updates/2026-05-04 https://eventris.app/drug-safety/codeine-linctus-reclassified-to-prescription-only-medicine/2026-05-04 https://eventris.app/drug-safety/pseudoephedrine-and-risk-of-pres-and-rcvs/2026-05-03 https://eventris.app/drug-safety/january-2024-medicine-recalls-and-safety-updates/2026-05-03 https://eventris.app/drug-safety/valproate-safety-materials-for-under-55s/2026-05-03 https://eventris.app/drug-safety/fluoroquinolone-antibiotics-restricted-prescribing-now-in-effect/2026-05-02